James Adams joined Sonoma in January of 2021 and has over 27 years of experience across a wide range of disciplines including research and development, manufacturing and marketing and sales. He earned his B.S. in Microbiology from Michigan State University and his MBA from Rivier University. Prior to joining Sonoma, he served as Sr. Director of Clinical Resources at the Fred Hutchinson Cancer Research Center. In that role, James was responsible for building and leading the Therapeutic Products Program (TPP, aka clinical manufacturing) within Fred Hutch along with direct oversight of Shared Resource Cores including the Immune Monitoring Laboratory, Specimen Processing, Glassware, Media Prep and Research Cell Bank.
Within TPP, James had direct responsibility for Process Development, Quality Control, Quality Assurance, Program and Project Management and two separate cGMP manufacturing facilities. One facility was focused primarily on biologics-based products including monoclonal antibodies, radioimmunotherapies, plasmid vaccines and lentiviral vectors. The other facility was focused on cellular therapies with a strong emphasis on CAR-T, TCR and NK-derived treatments (both autologous and allogeneic). During his tenure at Fred Hutch, James was responsible for over 20 separate Phase I/II clinical trials and the successful generation of over 500 therapies.